D. Boral Capital has maintained a Buy recommendation for MediciNova (MNOV). The average one-year price target suggests a 357.69% upside, with institutional ownership showing some increases in certain funds, though overall shares owned by institutions decreased. The put/call ratio indicates a bullish outlook for the stock.

美第奇新星生物技術

<p>D. Boral Capital 對 MediciNova (MNOV) 維持了買入評級。平均一年價格目標顯示出 357.69% 的上漲空間，儘管整體機構持股減少，但某些基金的機構持股有所增加。看跌/看漲比率表明對該股票的看漲前景</p>

D. Boral Capital 維持對美第奇新星生物技術（MediciNova，MNOV）的買入建議